Q&A Genmab 2021-08-26

	26/8 12:03 af Jan Van de Winkel	With all the exciting news and rapid development, the second quarter of 2021 also marked some important milestones for Genmab on our organizational growth journey, when we welcomed our employee no 1,000 and laid down the foundational stone for our new HQ building in Valby, Copenhagen..
	26/8 12:02 af Jan Van de Winkel	DARZALEX continues to evolve with additional approvals in both Europe and the US, and has now been part of the treatment regimen for over 200,000 patients..
	26/8 12:02 af Jan Van de Winkel	As we shared with you last quarter, the PDUFA target date for a potential U.S. FDA approval is October of this year. Along with our partner Seagen, we look forward to updating you on the progress of tisotumab vedotin in metastatic cervical cancer in due course..
	26/8 12:01 af Jan Van de Winkel	Data from the clinical trial on which the tisotumab vedotin BLA was based, the innovaTV 204 Phase 2 study, was recently published in The Lancet Oncology..
	26/8 12:01 af Jan Van de Winkel	This is the first regulatory approval for a therapy created using our proprietary DuoBody technology, and we hope this is the first validation of many of the major potential of this innovative technology to create truly differentiated bispecific antibody therapeutics..
	26/8 12:01 af Jan Van de Winkel	In May Janssen received FDA approval for RYBREVANT for patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations..
	26/8 12:00 af Jan Van de Winkel	Recent highlights include..
	26/8 12:00 af Helge Larsen/PI-redaktør	Can you give us a short-term update on key figures for H1 and important events in Q2?
	26/8 12:00 af Jan Van de Winkel	Thanks - fire away.
	26/8 11:59 af Helge Larsen/PI-redaktør	Jan van de Winkel, Andrew Carlsen and Nicolai Søberg-Hansen. Welcome to Q&A here on ProInvestor.com. We are very happy to have you here and ready to answer questions from our investors.
	26/8 11:59 af Jan Van de Winkel	Thank you for once again inviting us to talk about Genmab’s results for H1 2021.
	26/8 11:59 af Jan Van de Winkel	We are here..
	26/8 11:59 af Jan Van de Winkel	Hello all,
	26/8 11:58 af Helge Larsen/PI-redaktør	Jan, Nicolai and Andrew. Are you online?
	26/8 11:06 af Helge Larsen/PI-redaktør	Q&A starter kl. 13.